Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sichuan Biokin Pharmaceutical Co's Pretax Margin % or its related term are showing as below:
SHSE:688506'
s Pretax Margin % Range Over the Past 10 Years
Min: -136.87 Med: 2.41 Max: 68.32
Current: -50.12
SHSE:688506's Pretax Margin % is ranked worse than 85.85% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.11
vs SHSE:688506: -50.12
Sichuan Biokin Pharmaceutical Co (SHSE:688506) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Sichuan Biokin Pharmaceutical Co Pretax Margin % Related Terms
Sichuan Biokin Pharmaceutical Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Biokin Pharmaceutical Co Pretax Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sichuan Biokin Pharmaceutical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Biokin Pharmaceutical Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sichuan Biokin Pharmaceutical Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Sichuan Biokin Pharmaceutical Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Biokin Pharmaceutical Co (SHSE:688506) has a Pretax Margin % of -971.90% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sichuan Biokin Pharmaceutical Co and its competitors. According to the industry distribution chart, Sichuan Biokin Pharmaceutical Co ranks #825 out of 961 companies in the Drug Manufacturers industry, placing it in the top 85.8%.
Is Sichuan Biokin Pharmaceutical Co's Pretax Margin % too high?
Sichuan Biokin Pharmaceutical Co's current Pretax Margin % is -971.90%. Based on the distribution chart, Sichuan Biokin Pharmaceutical Co ranks #825 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sichuan Biokin Pharmaceutical Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Biokin Pharmaceutical Co's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sichuan Biokin Pharmaceutical Co ranks #825 out of 961 companies for Pretax Margin %. This places Sichuan Biokin Pharmaceutical Co in the lower half of its industry. The industry median Pretax Margin % is 7.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.11, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sichuan Biokin Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Biokin Pharmaceutical Co's current Pretax Margin % is -971.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Biokin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Biokin Pharmaceutical Co (SHSE:688506) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥287.73, compared to a current price of ¥238.62 — trading 17.1% below its estimated fair value. The current Pretax Margin % is -971.90%. Sichuan Biokin Pharmaceutical Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Sichuan Biokin Pharmaceutical Co (SHSE:688506), the current Pretax Margin % is -971.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Biokin Pharmaceutical Co (SHSE:688506) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Biokin Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥238.62 is trading 17.1% below its estimated GF Value™ of ¥287.73.
GuruFocus considers Sichuan Biokin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688506:
Pretax Margin %: -971.90%
GF Value™: ¥287.73 vs. price of ¥238.62 (17.1% below fair value)
No single metric tells the full story. See the SHSE:688506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing.
79GF Score
Get the complete analysis for SHSE:688506
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688506 has been successfully added to your 
